Clinical Trial

Prevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease

Study acronym: OSAPAD
Recruiting
View on ClinicalTrials.gov →
Summary
Obstructive sleep apnea syndrome (OSAS) is characterized by partial (hypopnea) or complete (apnea) obstruction of the upper airways, leading to intermittent hypoxemia and sleep fragmentation. Peripheral arterial occlusive disease (PAOD) is a chronic condition defined by the narrowing or occlusion of arteries in the lower limbs, often resulting in ischemia of downstream tissues. This disease is a common complication of atherosclerosis and affects approximately 1.2% of the general French population. OSAS is a well-established risk factor for atherosclerotic disease, particularly for coronary and neurovascular events. Although a relationship between OSAS and PAOD has been investigated in recent years, the link has not been definitively established and requires further study. Therefore, this preliminary cohort study aims to observe the prevalence of OSAS among patients diagnosed with PAOD, regardless of the disease stage.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-12-02; most recent amendment 2026-07-06.
Trial Details
NCT Number NCT07283289
Lead Sponsor Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Conditions Peripheral Artery Disease
Enrollment 295 participants
Start Date 2025-11-05
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-07